重视肝硬化腹水及其并发症的防治研究

doi:10.3969/j.issn.1672-5069.2014.04.001

Abstract

Wang Yuming. Prevention and treatment of ascites and its complications in patients with liver cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(4): 337-340.

[1] Runyon BA. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline:management of adult patients with ascites due to cirrhosis 2012. Hepatology,2013,57（4）:1651-1653.
[2] 王宇明. 肝硬化合并低钠血症-顽固性腹水-急性肾损伤的防治新认识. 中华肝脏病杂志,2012,20（7）:481-486.
[3] 中华医学会感染病学分会肝衰竭与人工肝学组和肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南.实用肝脏病杂志,2013,16（3）：210-216.
[4] Torres VE,Chapman AB,Devuyst O,et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med,2012,367（25）:2407-2418.
[5] Okita K,Kawazoe S,Hasebe C,et al. Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema:A randomized,double-blind,placebo-controlled trial. Hepatol Res,2014,44（1）:83-91.
[6] Sakaida I,Kawazoe S,Kajimura K,et al. Tolvaptan for improvement of hepatic edema: A phase 3,multicenter,randomized,double-blind,placebo-controlled trial. Hepatol Res,2014,44（1）:73-82.
[7] Gines P,Angeli P,Lenz K,et al.EASL clinical practice guidelines on the management of ascites,spontaneous bacterial peritonitis,and hepatorenal syndrome in cirrhosis. J Hepatol,2010,53（3）: 397-417.
[8] 王宇明. 重症感染的临床诊治进展. 第三军医大学学报, 2011,33（21）:2219-2222.
[9] Lontos S,Shelton E,Angus PW,et al. A randomised controlled study of trimethoprim-sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients. J Dig Dis,2014,15（5）:260-267.
[10] Lee YY,Tee HP,Mahadeva S.Role of prophylactic antibiotics in cirrhotic patients with variceal bleeding. World J Gastroenterol,2014,20（7）:1790-1796.
[11] Quinlan GJ,Martin GS,Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology,2005,41（6）:1211-1219.
[12] Garcia-Martinez R,Caraceni P,Bernardi M,et al. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology,2013,58（5）:1836-1846.
[13] Maitland K,Pamba A,English M,et al. Randomized trial of volume expansion with albumin or saline in children with severe malaria:preliminary evidence of albumin benefit. Clin Infect Dis, 2005,40（4）:538-545.
[14] Chen TA,Tsao YC,Chen A,et al. Effect of intravenous albumin on endotoxin removal,cytokines,and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis. Scand J Gastroenterol,2009,44（5）:619-625.
[15] Fernandez J,Monteagudo J,Bargallo X,et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology,2005,42（3）:627-634.
[16] Salerno F,Navickis RJ,Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis:a meta-analysis of randomized trials. Clin Gastroenterol Hepatol,2013,11（2）:123-130.

Prevention and treatment of ascites and its complications in patients with liver cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[3]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[4]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[5]	Wang Yueyuan, Wang Yan, Zhang Dandan. Short-term efficacy of terlipressin and octreotide combination in treatment of cirrhotic patients complicated by hepatorenal syndrome [J]. Journal of Practical Hepatology, 2019, 22(5): 684-687.
[6]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[7]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.
[8]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[9]	Zhao Fangfang, Zhai Yongzhen, Feng Guohe. Efficacy and safety of autologous peripheral blood stem cell transplantation in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 700-703.
[10]	Chen Shan, Zhuang Huashuai, Xing Yixi, et al. Preventive application of meropenem in patients with liver cirrhosis complicated by upper gastrointestinal bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 704-707.
[11]	Xu Qilin, Hao Shaohuan, Ran Bo. Risk factors of portal vein thrombosis after splenectomy in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2019, 22(5): 708-711.
[12]	Jin Lianghong, Li Xingjie, Guan Hongbo, et al. Clinical value of dual-energy CT iodine quantification combined with dynamic contrast-enhanced MRI in evaluating hepatic hemodynamics and liver functions in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 712-715.
[13]	Bian Xinqu, Chen Jie, Liu Yanmin, et al. Serum thyroid hormone level changes in patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy [J]. Journal of Practical Hepatology, 2019, 22(5): 716-719.
[14]	Xiao Han, Wang Li. Mechanisms of thrombocytopenia in liver cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 462-465.
[15]	Han Meiling, Chen Ping. Antiviral therapy in patients with liver cirrhosis and thrombocytopenia [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 466-469.